Novel targets in the regulation of NF-kB and SREBP activity: A two-faceted approa

NF-kB 和 SREBP 活性调节的新目标:两方面的方法

基本信息

  • 批准号:
    8045247
  • 负责人:
  • 金额:
    $ 15.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-30 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetes has become an increasingly serious epidemic in recent years, with CDC estimates of 24 million people directly affected in the United States alone. There are two interconnected pathways that are critical in the onset of diabetes. They are the nutritionally-derived metabolic pathway, and the pro-inflammatory pathway. Aberrant activation of both the above pathways is commonly found to be associated with the pathological progression of diabetes. We have identified two novel transcription activator-Mediator interactions that control and regulate the metabolic and inflammatory pathway. The two transcription activators, NF-:B (Nuclear Factor- :B) and SREBP (Sterol Regulatory Element-Binding Protein), play significant roles in the onset and progression of diabetes. Both these factors have been shown to functionally interact with a co-activator known as the Activator Recruited Co-factor(ARC)/Mediator Complex. NF-:B and SREBP are critical in regulating the expression of a number of genes involved in the onset of diabetes. We propose to target the activator-Mediator interaction of these two transcription factors (SREBP and NF-:B) with small molecular effectors, thus inhibiting gene activation. The activator-Mediator interactions of SREBP and NF-:B represent novel targets because their inhibition would affect the most downstream element in their activation pathways. We will determine the structure of the minimal elements that constitute the interaction (i.e. the complex of KIX domain in the Mediator with the transactivation domain (TAD) of the activator) by solution state NMR. We will identify small molecule inhibitors for each of the activator-Mediator interactions by high-throughput screening and validate them in an in vitro transcription assay. We will subsequently study the effect of these inhibitors on gene transcription and adipocyte differentiation, in vivo (cell culture), in 3T3-L1 pre-adipocyte cells. This will form the basis for future studies wherein the inhibitors identified and characterized here, will be tested in C.elegans and diabetic murine models. In addition, we seek to elucidate a novel mechanism of regulation of SREBP target genes orchestrated by let-7 micro-RNA. Micro-RNAs are known to modulate mRNA levels of a set of genes, thus synergistically regulating an entire pathway. We hypothesize let-7 modulates levels of PGC-1 co-activators, which in turn regulates SREBP target genes, and is expected to have profound implications in lipogenesis and mitochondrial biogenesis. PUBLIC HEALTH RELEVANCE: Diabetes has become an increasingly serious epidemic in recent years. The nutritionally-derived metabolic pathway and the pro-inflammatory pathways are critical in the onset of diabetes and we have identified two novel transcription activator-Mediator interactions that control and regulate these pathway. We intend to target gene activation in these pathways by identifying small molecule inhibitors for the activator-Mediator interactions and understand endogenous gene regulation by micro-RNAs in these pathways.
描述(由申请人提供):近年来,糖尿病已成为一种日益严重的流行病,CDC估计仅在美国就有2400万人直接受影响。有两个相互关联的途径在糖尿病的发病中至关重要。它们是营养来源的代谢途径和促炎途径。通常发现上述两种途径的异常激活与糖尿病的病理进展相关。我们已经确定了两种新型转录激活因子-介体相互作用,可以控制和调节代谢和炎症途径。两种转录激活因子NF-:B(核因子-:B)和SREBP(固醇调节元件结合蛋白)在糖尿病的发生和发展中起重要作用。这两种因子已被证明在功能上与被称为激活剂募集辅因子(ARC)/介体复合物的辅激活剂相互作用。NF-:B和SREBP在调节参与糖尿病发病的许多基因的表达中是关键的。我们建议用小分子效应物靶向这两种转录因子(SREBP和NF-:B)的激活剂-介体相互作用,从而抑制基因激活。SREBP和NF-:B的激活剂-介体相互作用代表了新的靶点,因为它们的抑制会影响其激活途径中的最下游元件。我们将通过溶液状态NMR确定构成相互作用的最小元素的结构(即,介体中的KIX结构域与激活剂的反式激活结构域(KIX)的复合物)。我们将通过高通量筛选确定每个激活剂-介体相互作用的小分子抑制剂,并在体外转录测定中验证它们。随后,我们将研究这些抑制剂对基因转录和脂肪细胞分化的影响,在体内(细胞培养),在3 T3-L1前脂肪细胞。这将形成未来研究的基础,其中本文鉴定和表征的抑制剂将在秀丽隐杆线虫和糖尿病小鼠模型中进行测试。此外,我们试图阐明一种新的机制,SREBP靶基因的调控精心策划的let-7 micro-RNA。已知微RNA调节一组基因的mRNA水平,从而协同调节整个途径。我们假设let-7调节PGC-1共激活因子的水平,PGC-1共激活因子反过来调节SREBP靶基因,并且预计在脂肪生成和线粒体生物生成中具有深远的意义。 公共卫生相关性:近年来,糖尿病已成为一种日益严重的流行病。营养来源的代谢途径和促炎途径在糖尿病的发病中至关重要,我们已经确定了两种新的转录激活因子-介体相互作用,控制和调节这些途径。我们打算通过识别激活剂-介体相互作用的小分子抑制剂来靶向这些途径中的基因激活,并了解这些途径中微小RNA的内源性基因调控。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Haribabu Arthanari其他文献

Haribabu Arthanari的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Haribabu Arthanari', 18)}}的其他基金

NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10591671
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10594969
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10377588
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10392661
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10387787
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins
NMR 指纹图谱:利用最佳控制脉冲设计、定制同位素标记和机器学习来研究棘手的蛋白质
  • 批准号:
    10159285
  • 财政年份:
    2020
  • 资助金额:
    $ 15.14万
  • 项目类别:
Novel targets to regulate NF-kB & SREBP activity: an approach to combat diabetes
调节 NF-kB 的新靶点
  • 批准号:
    8150351
  • 财政年份:
    2010
  • 资助金额:
    $ 15.14万
  • 项目类别:
Novel targets to regulate NF-kB & SREBP activity: an approach to combat diabetes
调节 NF-kB 的新靶点
  • 批准号:
    8318211
  • 财政年份:
    2010
  • 资助金额:
    $ 15.14万
  • 项目类别:

相似国自然基金

miR-29a "targets" PPAR δ对心力衰竭的作用及作为潜在标志物的研究
  • 批准号:
    81371895
  • 批准年份:
    2013
  • 资助金额:
    70.0 万元
  • 项目类别:
    面上项目

相似海外基金

DISCOVERY OF NOVEL TARGETS FOR POST-TRAUMATIC HEADACHE
发现创伤后头痛的新靶标
  • 批准号:
    10685784
  • 财政年份:
    2023
  • 资助金额:
    $ 15.14万
  • 项目类别:
Identifying novel molecular targets, signaling pathways and mechanisms underlying fentanyl overdose-induced severe respiratory depression and lethality in rats using TMT phosphoproteomics/proteomics
使用 TMT 磷酸蛋白质组学/蛋白质组学识别芬太尼过量引起大鼠严重呼吸抑制和致死的新分子靶标、信号通路和机制
  • 批准号:
    10831163
  • 财政年份:
    2023
  • 资助金额:
    $ 15.14万
  • 项目类别:
Uncovering novel mechanisms and potential therapeutic targets for IgA vasculitis through GWAS and systems-level analysis of regulatory networks.
通过 GWAS 和调节网络的系统级分析揭示 IgA 血管炎的新机制和潜在治疗靶点。
  • 批准号:
    10723651
  • 财政年份:
    2023
  • 资助金额:
    $ 15.14万
  • 项目类别:
Novel targets of CRL4 ligase within Cohesinopathy pathways
CRL4 连接酶在粘连病途径中的新靶标
  • 批准号:
    10699961
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
生长激素对非酒精性脂肪肝影响的代谢组学研究:新型生物标志物和治疗靶点的鉴定
  • 批准号:
    10451082
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Evaluating novel architectural proteins as therapeutic targets for cohesin dysfunction
评估新型结构蛋白作为粘连蛋白功能障碍的治疗靶点
  • 批准号:
    10593249
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Novel targets of CRL4 ligase within Cohesinopathy pathways
CRL4 连接酶在粘连病途径中的新靶标
  • 批准号:
    10349922
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Evaluating novel architectural proteins as therapeutic targets for cohesin dysfunction
评估新型结构蛋白作为粘连蛋白功能障碍的治疗靶点
  • 批准号:
    10709896
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
生长激素对非酒精性脂肪肝影响的代谢组学研究:新型生物标志物和治疗靶点的鉴定
  • 批准号:
    10608193
  • 财政年份:
    2022
  • 资助金额:
    $ 15.14万
  • 项目类别:
Novel Targets and Therapeutic Interventions against Cerebral Ischemia-Reperfusion Injury
脑缺血再灌注损伤的新靶点和治疗干预措施
  • 批准号:
    10297340
  • 财政年份:
    2021
  • 资助金额:
    $ 15.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了